Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 21;22(1):609.
doi: 10.1186/s12877-022-03296-w.

Prevalence and patterns of the concurrent use of anticholinergics for the motor symptoms of Parkinson's disease and acetylcholinesterase inhibitors in Parkinson's disease patients with dementia: a cross-sectional study using Korea National Health Insurance claims data

Deborah Baik  1 , Yun Mi Yu  1 , Sun-Young Jung  2 , Hye-Young Kang  3
Affiliations

Prevalence and patterns of the concurrent use of anticholinergics for the motor symptoms of Parkinson's disease and acetylcholinesterase inhibitors in Parkinson's disease patients with dementia: a cross-sectional study using Korea National Health Insurance claims data

Deborah Baik et al. BMC Geriatr. .

Abstract

Background: The concurrent use of anticholinergics and acetylcholinesterase inhibitors (ACHEIs) in Parkinson's disease (PD) patients with dementia should be avoided because the opposing pharmacological actions of both drugs reduce the treatment efficacy. We aimed to investigate the prevalence of the concurrent use of these two types of drugs in Korean patients.

Methods: In the 2017 Health Insurance Review and Assessment Service-National Aged Patient Sample data, comprising insurance claims records for a 10% random sample of patients aged ≥ 65 years in Korea, "concurrent use" was defined as the overlapping of anticholinergic and ACHEI doses for at least 2 months.

Results: Among 8,845 PD patients with dementia, 847 (9.58%) were co-administered anticholinergics, used to treat the motor symptoms of PD, and ACHEIs for a mean duration of 7.7 months. A total of 286 (33.77% of all co-administered) patients used both drug types concurrently all year. About 80% of concurrent users were prescribed each drug by the same prescriber, indicating that coadministration may not be due to a lack of information sharing between providers. Logistic regression analysis showed that patients mainly treated at clinics (odds ratio (OR), 1.541; 95% confidence interval (CI), 1.158-2.059), hospitals (OR, 2.135; 95% CI, 1.586-2.883), and general hospitals (OR, 1.568; 95% CI, 1.221-2.028) were more likely to be co-prescribed anticholinergics and ACHEIs than those mainly treated at tertiary-care hospitals. PD patients with dementia treated at healthcare organizations located in areas other than the capital city had an approximately 22% higher risk of concurrent use (OR: 1.227, 95% CI: 1.046-1.441).

Conclusions: The concurrent use of anticholinergics for the motor symptoms of PD and ACHEIs in elderly Korean PD patients with dementia cannot be ignored, and strategies that mitigate potentially inappropriate concurrent drug use are required.

Keywords: Acetylcholinesterase inhibitor; Cholinergic antagonist; Dementia; Drug utilization; Insurance claims data; Parkinson’s disease.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there is no conflict of interest.

Figures

Fig. 1
Fig. 1
Distribution of the duration of concurrent use of anticholinergics used to treat the motor symptoms of Parkinson’s disease and ACHEIs in Parkinson’s disease patients with dementia. *ACHEI, acetylcholinesterase inhibitor
See this image and copyright information in PMC

References

    1. Kehagia AA, Barker RA, Robbins TW. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease. Lancet Neurol. 2010;9(12):1200–1213. doi: 10.1016/S1474-4422(10)70212-X. - DOI - PubMed
    1. Lee A, Gilbert RM. Epidemiology of Parkinson Disease. Neurol Clin. 2016;34(4):955–965. doi: 10.1016/j.ncl.2016.06.012. - DOI - PubMed
    1. Purves D, Augustine GJ, Fitzpatrick D, Hall WC, Lamantia A-S, Mcnamara JO, et al. Neuroscience: Sinauer Associates, Inc.; 2004.
    1. Mantri S, Fullard M, Gray SL, Weintraub D, Hubbard RA, Hennessy S, et al. Patterns of dementia treatment and frank prescribing errors in older adults with Parkinson Disease. JAMA Neurol. 2019;76(1):41–49. doi: 10.1001/jamaneurol.2018.2820. - DOI - PMC - PubMed
    1. Health Insurance Review and Assessment Service. Healthcare bigdata system. https://opendata.hira.or.kr/home.do. Accessed 10 Jan 2019.

Substances